(1) What are the reasons for not including the Medicines Control Council (MCC) in her department’s 2009-10 annual report; (2) whether any progress has been made with regard to the restructuring of the MCC; if not, (a) why not and (b) what are the reasons for the delay; if so, by which date will the new structure be put in place?